TransEnterix (NYSE:TRXC) said today that it agreed to deal its SurgiBot assets to Chinese medtech investment firm Great Belief International for $29 million. The agreement calls for Research Triangle Park, N.C.-based TransEnterix to retain the distribution rights to SurgiBot, which it shelved last year, outside of the U.S. The FDA in April 2016 denied 510(k) clearance for…